Syros Pharmaceuticals, Inc. (SYRS) Receives Average Rating of “Buy” from Analysts
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has earned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $26.37.
Several equities research analysts recently commented on SYRS shares. ValuEngine cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Cann reaffirmed a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a report on Monday, August 21st. Oppenheimer Holdings, Inc. set a $28.00 price target on Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Finally, JMP Securities raised Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a report on Thursday, September 28th.
In other Syros Pharmaceuticals news, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $22.00, for a total transaction of $72,204.00. Following the completion of the sale, the director now owns 420,101 shares of the company’s stock, valued at $9,242,222. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eric R. Olson sold 12,500 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total value of $273,125.00. Following the sale, the insider now directly owns 12,500 shares of the company’s stock, valued at approximately $273,125. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,564 shares of company stock valued at $476,803. 33.60% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of SYRS. Nationwide Fund Advisors increased its stake in Syros Pharmaceuticals by 249.8% during the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after acquiring an additional 5,016 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Syros Pharmaceuticals by 11,253.8% during the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after acquiring an additional 10,466 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Syros Pharmaceuticals during the first quarter worth $185,000. Rhumbline Advisers acquired a new stake in Syros Pharmaceuticals during the second quarter worth $198,000. Finally, New York State Common Retirement Fund increased its stake in Syros Pharmaceuticals by 167.9% during the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after acquiring an additional 8,399 shares during the last quarter. 59.61% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/syros-pharmaceuticals-inc-syrs-receives-average-rating-of-buy-from-analysts.html.
Syros Pharmaceuticals (NASDAQ:SYRS) traded up 2.47% during trading on Friday, hitting $16.58. The stock had a trading volume of 109,917 shares. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $17.89. The company’s 50 day moving average is $15.71 and its 200-day moving average is $15.71. The company’s market cap is $435.39 million.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, equities research analysts predict that Syros Pharmaceuticals will post ($2.09) earnings per share for the current year.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.